IP23: Prostate Cancer: Staging & Radiation Therapy
Friday, May 15, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Oncology: Prostate
Friday, May 15
IP23-02: 99mTc-PSMA-SPECT/CT vs. PSMA PET for Nodal Metastases Detection in Prostate Cancer Patients Undergoing PSMA-Radioguided Surgery during RARP with ePLND
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Andrea Cosenza · San Raffaele University Hospital, Milan, Italy
IP23-03: PSMA Radioguided Surgery for Lymph Node Metastases Detection in Prostate Cancer Patients Undergoing RARP with ePLND: Final Results of a Prospective Phase 2 Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Leonardo Quarta
IP23-04: Enhancing the Prediction of Adverse Pathology in Prostate Cancer by Combining PIRADS and Intraprostatic 68Ga-PSMA PET Features: The Role of P-score
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Paolo Zaurito · IRCSS San Raffaele Hospital, Milan, Italy
IP23-05: Assessing the Risk of False Positive Findings of PSMA-PET in Nodal Staging in Patients Treated With Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
IP23-06: PSMA Imaging-Based Stratification of Men with High-Risk Prostate Cancer Candidates for Radical Prostatectomy: Beyond Clinical Risk Factors
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
IP23-07: A Critical Appraisal of PSMA-PET Use for Primary Staging in Prostate Cancer Patients Undergoing Radical Prostatectomy: Is Molecular Imaging Always Needed?
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
IP23-08: Unfavorable Histologic Classifier Enhances Prognostic Accuracy of NCCN Intermediate-Risk Classification for Adverse Pathology at Radical Prostatectomy
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Mohamad Watfa · Cleveland Clinic
IP23-09: Identifying Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection among Prostate Cancer Patients with PSMA-PET–Detected Nodal Disease (miN1): The Combined Role of MRI Staging and Quantitative PSMA Parameters
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Simone Scuderi · Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University
IP23-10: The Impact of the 2025 NCCN Update in Defining Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Noriyoshi Miura · Ehime University
IP23-11: Prognostic Value of PSMA PET in Metachronous Oligometastatic Prostate Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Sebastian Hoberueck · Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
IP23-12: Diagnostic performance of preoperative PSMA PET for nodal staging and prediction of long-term biochemical recurrence in patients undergoing robotic prostatectomy
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Sivaraman C · Postgraduate Institute of Medical Education And Research, Chandigarh
IP23-13: Integrating PSMA PET CT and MSKCC Nomogram to Refine Indications for Pelvic Lymph Node Dissection in Intermediate and High Risk Prostate Cancer - A Retrospective cohort study from a tertiary care cancer center
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Praveen Balagangatharan · Basavatarakam Indo American Cancer Hospital
IP23-14: Machine Learning Based Quantification of Gleason Pattern 4 on Prostate Biopsy: proof of principle study comparing measurement approaches
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Andrew Vickers · Memorial Sloan Kettering Cancer Center
IP23-15: Spatial Distribution of PSMA PET–Positive Lesions in Biochemical Recurrence After Radical Prostatectomy According to Decipher Genomic Classifier
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Mohammed Shahait · University of California Irvine
IP23-16: A pelvic MRI for biochemical recurrence of prostate cancer after radical prostatectomy stratifies outcomes for salvage radiation vs observation
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Nancy Wei · Mayo Clinic
IP23-17: Baseline frailty, treatment intensity, and clinical outcomes among older adults with locally advanced prostate cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Agustin Perez-Londono
IP23-18: SUMOylation-Mediated RAD51 Activation Fuels Homologous Recombination Repair and Radiotherapy Resistance in Prostate Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Jiayin Chen · the first affiliated hospital of Fujian Medical University
IP23-19: Impact of Prior Chemotherapy on Survival and Safety Outcomes of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Hisanori Taniguchi · Kansai Medical University
IP23-20: Global Gaps in ADT Use with Radiation for Localized Prostate Cancer: Lessons from the TrueNTH Global Registry
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Stacy Piva
IP23-21: Complications and Retreatment Rates of Radiation Therapy for Prostate Cancer compared to Radical Prostatectomy: A Real-Life, Nation-Wide Observational Study using the Epic Cosmos Collaborative Database
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Luca Morgantini · University of Illinois at Chicago
IP23-22: Radiotherapy History Is Not Associated With Functional Satisfaction and Quality of Life Outcomes in Patients with Artificial Urinary Sphincters
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Vishu Chandrasekhar
IP23-23: Whole blood RNA-seq pre- vs. post-radiation in prostate cancer unveils transcriptomic alterations and baseline predictors of hematuria
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Benjamin George · Medical College of Wisconsin
IP23-24: Clinical Significance of Rectal Wall Infiltration by Hydrogel Spacer on Treatment Outcomes and Rectal Dosimetry in Prostate Cancer Patients Undergoing Trimodality Therapy
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Hiromi Sato
IP23-25: Impact of spaceOAR hydrogel on rectal bleeding following cyberknife stereotactic body radiation therapy for prostate cancer: A 628-patient retrospective study
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Isabel Guan · SUNY Downstate COM
IP23-26: Prospective Evaluation of Sexual Function Over 5 Years in Patients with Localized Prostate Cancer Treated with Carbon-Ion Radiotherapy.
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Yoshiyuki Miyazawa · Gunma University
IP23-27: Hypofractionated Salvage Radiation Therapy in Biochemical Recurrence of Prostate Cancer: Acute Toxicity and Timing Insights
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Nicole Arbex
IP23-28: Development of bladder and rectal cancer in patients with prostate cancer treated by surgery or radiotherapy
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Pau Martinez Rodriguez · Hospital of Manises
IP23-29: Contextual Reasoning in a Locally Deployed Large Language Model Outperforms Manual Abstraction for Prostate Biopsy Pathology
Friday, May 15, 2026 3:30 PM to 5:30 PM
147A
Salim Younis · Cleveland Clinic Foundation
